SS
LRMR icon

Sunbelt Securities’s Larimar Therapeutics LRMR Stock Holding History

Sunbelt Securities’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26
Closed -$99 – 3048
2025
Q4 		$99 Buy
26
+22
+550% +$86 ﹤0.01% 2543
2025
Q3 		$13 Buy
+4
New +$15 ﹤0.01% 2674

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Sunbelt Securities's LRMR Position: Q1 2026 in Review

Sunbelt Securities sold out of Larimar Therapeutics (LRMR) in Q1 2026, closing a stake of 26 shares — an estimated $99 sold.

Sunbelt Securities first reported a position in LRMR in Q3 2025 and held it in 2 quarters. The position peaked at $99 in Q4 2025. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Sunbelt Securities reported no remaining Larimar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sunbelt Securities sold 26 Larimar Therapeutics shares in Q1 2026, an estimated $99.
  • Sunbelt Securities first reported a position in Larimar Therapeutics in Q3 2025 and held it in 2 quarters.
  • Sunbelt Securities's Larimar Therapeutics position peaked at $99 in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.